Opinion

Video

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      4 experts in this video
      Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
      Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
      Study findings highlight gender gaps in oncology authorship and citation
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      4 experts in this video
      Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
      4 experts in this video
      Non–Muscle Invasive-Bladder Cancer Overview
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
      Expert discusses the NMIBC trials landscape
      Related Content
      Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients
      June 11th 2025

      Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients

      Cleveland Clinic
      Glean™ Urodynamics System developed by Bright Uro based on foundational technology created at Cleveland Clinic; Device received FDA clearance earlier this year
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 9th 2025

      En bloc resection of bladder tumor: Is it the way forward?

      Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
      "As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      FDA updates in urology: May 2025
      June 2nd 2025

      FDA updates in urology: May 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from May 2025.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 1st 2025

      NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

      Benjamin P. Saylor
      The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.
      © 2025 MJH Life Sciences

      All rights reserved.